AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16671428 — intervention group
Group type: EXPERIMENTAL
Intervention: SAH and ROSC‐SAH
Number of subjects: 143
Study 14581254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg with moderate intensity counseling
Number of subjects: 1524
Study 14581254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg with moderate intensity counseling
Number of subjects: 1524
Study 14581254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg
Number of subjects: 1524
Study 14581254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg
Number of subjects: 1524
Study 11002229 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal external beam radiation therapy
Number of subjects: 43
Study 8971287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 200 mg
Number of subjects: 0
Study 8971287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg
Number of subjects: 0
Study 8971287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 800 mg
Number of subjects: 0
Study 8971287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 150 mg
Number of subjects: 0
Study 8971287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (all doses)
Number of subjects: 0
Study 8971287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1593689 — intervention group
Group type: EXPERIMENTAL
Intervention: site release vaginal pH buffer cream
Number of subjects: 12
Study 1593689 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 6520800 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 42
Study 30951602 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan
Number of subjects: 49
Study 30951602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 28791531 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial-behavioral intervention
Number of subjects: 199
Study 28791531 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 199
Study 27267710 — intervention group
Group type: COMPARATOR
Intervention: Probiotic Visbiome at 900 billion bacteria daily
Number of subjects: 76
Study 25059544 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip on Challenging Behavior care program
Number of subjects: 17
Study 22678090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure-lowering treatment
Number of subjects: 404
Study 20175871 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket cards (PC)
Number of subjects: 1085
Study 20175871 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket digital assistant (PDA)
Number of subjects: 1085
Study 20175871 — intervention group
Group type: EXPERIMENTAL
Intervention: eAlerts
Number of subjects: 1085
Study 20175871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CDSS)
Number of subjects: 1085
Study 17535839 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1740
Study 17535839 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1740
Study 17535839 — intervention group
Group type: COMPARATOR
Intervention: Smaller practice size (greater than eight GPs)
Number of subjects: 1740
Study 17535839 — intervention group
Group type: COMPARATOR
Intervention: Older GPs
Number of subjects: 1740
Study 16036009 — intervention group
Group type: EXPERIMENTAL
Intervention: Home videoconferencing (n = 14)
Number of subjects: 36
Study 16036009 — intervention group
Group type: COMPARATOR
Intervention: Ad hoc telephone support (n = 9)
Number of subjects: 36
Study 16036009 — intervention group
Group type: COMPARATOR
Intervention: Regular telephone calls (n = 13)
Number of subjects: 36
Study 12107216 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 86
Study 12107216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 10443602 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 39
Study 10443602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 39
Study 10443602 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 39
Study 10443602 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane and Sevoflurane
Number of subjects: 39
Study 10443602 — intervention group
Group type: COMPARATOR
Intervention: All three anesthetic agents
Number of subjects: 39
Study 7484061 — intervention group
Group type: EXPERIMENTAL
Intervention: Posatirelin
Number of subjects: 0
Study 7484061 — intervention group
Group type: COMPARATOR
Intervention: Citicoline
Number of subjects: 0
Study 7484061 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid
Number of subjects: 0
Study 1978862 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist
Number of subjects: 75
Study 1978862 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-receptor antagonist, local decongestants, and antiseptic gargles
Number of subjects: 75
Study 1978862 — intervention group
Group type: COMPARATOR
Intervention: Alum, salt or Dispirin gargles
Number of subjects: 75
Study 895764 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate regional-lymph-node dissection
Number of subjects: 553
Study 895764 — intervention group
Group type: COMPARATOR
Intervention: Delayed regional-lymph-node dissection (at the time of appearance of metastases)
Number of subjects: 553
Study 31848626 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance group
Number of subjects: 151
Study 31848626 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength group
Number of subjects: 151
Study 31848626 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 151
Study 31768803 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan plus activated vitamin D (calcitriol) 0.5 μg/day
Number of subjects: 0
Study 31768803 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg/day
Number of subjects: 0
Study 30700351 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B combined with autologous serum injection
Number of subjects: 96
Study 30700351 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B alone (Control group)
Number of subjects: 96
Study 28866453 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponseti method
Number of subjects: 15
Study 28866453 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 15
Study 26179651 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist delivered cognitive behavioural therapy (TCBT) plus treatment as usual (TAU)
Number of subjects: 495
Study 26179651 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioural therapy (WBCBT) plus treatment as usual (TAU)
Number of subjects: 495
Study 26179651 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 495
Study 23864492 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months bicycle endurance training
Number of subjects: 13
Study 23864492 — intervention group
Group type: COMPARATOR
Intervention: Reference group (males without diabetes)
Number of subjects: 13
Study 16968502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg q.a.m.
Number of subjects: 39
Study 16968502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 16968502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Pantoprazole and Placebo)
Number of subjects: 39
Study 15220766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 320
Study 15220766 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 320
Study 15220766 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 320
Study 15220766 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 320
Study 10731533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ovarian wedge resection (OWR)
Number of subjects: 12
Study 10731533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 9116222 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed stems
Number of subjects: 40
Study 9116222 — intervention group
Group type: COMPARATOR
Intervention: Unprimed stems
Number of subjects: 40
Study 1548525 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and doxorubicin (arm 1)
Number of subjects: 80
Study 1548525 — intervention group
Group type: EXPERIMENTAL
Intervention: VM-26 and Ara-C (arm 2)
Number of subjects: 80
Study 1548525 — intervention group
Group type: COMPARATOR
Intervention: Overall treatment
Number of subjects: 80
Study 2860990 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (100 mg twice a day, increased to a maximum of 400 mg twice a day)
Number of subjects: 174
Study 2860990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 31515736 — intervention group
Group type: EXPERIMENTAL
Intervention: Full team training program (didactic training and virtual simulation)
Number of subjects: 207
Study 31515736 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic part of the training program
Number of subjects: 207
Study 31515736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 207
Study 27995340 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphism in TXBA2R (rs1131882)
Number of subjects: 303
Study 26093794 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical intervention for diabetic foot ulcers
Number of subjects: 0
Study 24225010 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) with home exercise (HE)
Number of subjects: 241
Study 24225010 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised rehabilitative exercise plus home exercise (HE)
Number of subjects: 241
Study 24225010 — intervention group
Group type: COMPARATOR
Intervention: Home exercise (HE) alone
Number of subjects: 241
Study 21178182 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial implanting (I-implant)
Number of subjects: 291
Study 21178182 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal implanting (T-implant)
Number of subjects: 291
Study 21178182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ractopamine hydrochloride (RAC, 200 mg/(animal/d))
Number of subjects: 291
Study 21178182 — intervention group
Group type: EXPERIMENTAL
Intervention: I-implant
Number of subjects: 291
Study 21178182 — intervention group
Group type: EXPERIMENTAL
Intervention: T-implant
Number of subjects: 291
Study 21178182 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC
Number of subjects: 291
Study 21178182 — intervention group
Group type: COMPARATOR
Intervention: TRT1 and TRT2 (1 implant)
Number of subjects: 291
Study 19154822 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 198
Study 19154822 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 198
Study 19154822 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see approach with ergonomic advice
Number of subjects: 198
Study 17705242 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced targeted biopsy (5 cores)
Number of subjects: 100
Study 17705242 — intervention group
Group type: COMPARATOR
Intervention: Systematic biopsy (10 cores)
Number of subjects: 100
Study 17705242 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced targeted biopsy cores
Number of subjects: 100
Study 17705242 — intervention group
Group type: COMPARATOR
Intervention: Systematic biopsy cores
Number of subjects: 100
Study 14756612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 73
Study 14756612 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 73
Study 11123733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (0.3-3 mg x kg(-1))
Number of subjects: 335
Study 11123733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 11214557 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) for 5 days
Number of subjects: 335
Study 11214557 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (A-C) for 10 days
Number of subjects: 335
Study 11214557 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin estolate (EE) for 10 days
Number of subjects: 335
Study 8206813 — intervention group
Group type: EXPERIMENTAL
Intervention: Local union formalization
Number of subjects: 539
Study 8206813 — intervention group
Group type: EXPERIMENTAL
Intervention: Local union centralization
Number of subjects: 539
Study 2521549 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 1012
Study 2521549 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 1012
Study 2521549 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 1012
Study 2521549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 1012
Study 2521549 — intervention group
Group type: COMPARATOR
Intervention: Volatile anesthetics
Number of subjects: 1012
Study 2521549 — intervention group
Group type: EXPERIMENTAL
Intervention: All anesthetics
Number of subjects: 1012
Study 31764984 — intervention group
Group type: EXPERIMENTAL
Intervention: High dialysate Mg (2.0 mEq/L)
Number of subjects: 57
Study 31764984 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate Mg (1.0 mEq/L)
Number of subjects: 57
Study 30580460 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin + furosemide (0·125%)
Number of subjects: 80
Study 30580460 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin (0·125%)
Number of subjects: 80
Study 30580460 — intervention group
Group type: EXPERIMENTAL
Intervention: furosemide (0·125%)
Number of subjects: 80
Study 30580460 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 28739832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 3220
Study 28739832 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 3220
Study 25306517 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate rotator cuff repair with capsular release (group I)
Number of subjects: 63
Study 25306517 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed rotator cuff repair after 6 months of rehabilitation (group II)
Number of subjects: 63
Study 25306517 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 63
Study 23538449 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test zone 1 (past‐year abstinence)
Number of subjects: 1037
Study 23538449 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test zone 2 (low‐risk drinking)
Number of subjects: 1037
Study 23538449 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test zone 3 (mild to moderate alcohol misuse)
Number of subjects: 1037
Study 23538449 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test zone 4 (severe alcohol misuse)
Number of subjects: 1037
Study 23538449 — intervention group
Group type: COMPARATOR
Intervention: Comparison of zone 4 to zone 2
Number of subjects: 1037
Study 21916619 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet Social Support Score (USSS)
Number of subjects: 190
Study 21916619 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet emotional social support
Number of subjects: 190
Study 21916619 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet instrumental social support
Number of subjects: 190
Study 19533481 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.i.d.)
Number of subjects: 64
Study 19533481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 16920680 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroFET 4 hand-grip dynamometer
Number of subjects: 0
Study 15111227 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback provided; St=1000 ms, ISI=2700 ms, order Co-St
Number of subjects: 0
Study 15111227 — intervention group
Group type: COMPARATOR
Intervention: No feedback; St=1000 ms, ISI=900 or 2700 ms
Number of subjects: 0
Study 15111227 — intervention group
Group type: EXPERIMENTAL
Intervention: St=50 ms, ISI=100, 300, 900, or 2700 ms
Number of subjects: 0
Study 15111227 — intervention group
Group type: EXPERIMENTAL
Intervention: St=1000 ms, ISI=100, 300, 900, or 2700 ms
Number of subjects: 0
Study 11259239 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone oral solution
Number of subjects: 78
Study 11259239 — intervention group
Group type: COMPARATOR
Intervention: Crushed prednisolone tablets
Number of subjects: 78
Study 9348384 — intervention group
Group type: EXPERIMENTAL
Intervention: Encircled mesh technique (Group A)
Number of subjects: 191
Study 9348384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonencircled mesh technique (Group B)
Number of subjects: 191
Study 9348384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed technique (Group C)
Number of subjects: 191
Study 8294084 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (2 mg tid)
Number of subjects: 17
Study 8294084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2436343 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemonetics Cell Saver
Number of subjects: 46
Study 2436343 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambro Hollow Fibre Hemofilter
Number of subjects: 46
Study 2436343 — intervention group
Group type: COMPARATOR
Intervention: Untreated oxygenator contents
Number of subjects: 46
Study 31732448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil Sublingual Tablet 30 mcg
Number of subjects: 0
Study 31732448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28974102 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 147
Study 28974102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 28028373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide inhalation
Number of subjects: 0
Study 28028373 — intervention group
Group type: COMPARATOR
Intervention: Pure oxygen inhalation (Control)
Number of subjects: 0
Study 24328992 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreControl® (CC)
Number of subjects: 9
Study 24328992 — intervention group
Group type: EXPERIMENTAL
Intervention: ThermoTube (TT)
Number of subjects: 9
Study 22764846 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc (220 mg twice daily, equivalent to 50 mg elemental zinc twice daily)
Number of subjects: 58
Study 22764846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 20338667 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC-diagnosed SSI
Number of subjects: 54
Study 20338667 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC criteria
Number of subjects: 54
Study 20338667 — intervention group
Group type: EXPERIMENTAL
Intervention: ASEPSIS score
Number of subjects: 54
Study 18757665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg per day
Number of subjects: 3519
Study 18757665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 3519
Study 18757665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3519
Study 15844683 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure group treatment (n = 33)
Number of subjects: 58
Study 15844683 — intervention group
Group type: COMPARATOR
Intervention: Waiting period (n = 25)
Number of subjects: 58
Study 12190100 — intervention group
Group type: EXPERIMENTAL
Intervention: INF‐alpha + GM‐CSF for 3 months followed by INF‐alpha alone for 9 months (n = 23)
Number of subjects: 45
Study 12190100 — intervention group
Group type: COMPARATOR
Intervention: INF‐alpha for 12 months (n = 22)
Number of subjects: 45
Study 12190100 — intervention group
Group type: EXPERIMENTAL
Intervention: INF‐alpha + GM‐CSF
Number of subjects: 45
Study 12190100 — intervention group
Group type: COMPARATOR
Intervention: INF‐alpha
Number of subjects: 45
Study 11012554 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (Dox)
Number of subjects: 24
Study 11012554 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (Eto)
Number of subjects: 24
Study 11012554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (Ifo)
Number of subjects: 24
Study 8798375 — intervention group
Group type: EXPERIMENTAL
Intervention: ATLS course
Number of subjects: 32
Study 8798375 — intervention group
Group type: COMPARATOR
Intervention: non-ATLS group
Number of subjects: 32
Study 2050321 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (5 MU/m2 for 4 months and then 3 MU/m2 for another 8 months)
Number of subjects: 61
Study 2050321 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 61
Study 2050321 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b
Number of subjects: 61
Study 6860532 — intervention group
Group type: EXPERIMENTAL
Intervention: Metolazone 2.5 mg + Spironolactone 50 mg
Number of subjects: 12
Study 6860532 — intervention group
Group type: EXPERIMENTAL
Intervention: Metolazone 0.625 mg + Spironolactone 50 mg
Number of subjects: 12
Study 6860532 — intervention group
Group type: EXPERIMENTAL
Intervention: Metolazone 1.25 mg + Spironolactone 50 mg
Number of subjects: 12
Study 6860532 — intervention group
Group type: COMPARATOR
Intervention: Metolazone 2.5 mg alone
Number of subjects: 12
Study 31571095 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg twice daily
Number of subjects: 1509
Study 31571095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509
Study 31571095 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 1509
Study 31571095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonusers of statins
Number of subjects: 1509
Study 29073902 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed primary root canal filling (MPRCF: zinc oxide‐eugenol [ZOE], iodoform, calcium hydroxide)
Number of subjects: 155
Study 29073902 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide‐eugenol (ZOE)
Number of subjects: 155
Study 29073902 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitapex
Number of subjects: 155